MVZ CCB Frankfurt Und Main-Taunus GbR

The medical center is at the forefront of developing innovative strategies to mitigate contrast-associated acute kidney injury in patients undergoing infrainguinal peripheral vascular interventions. By employing automated Carbon Dioxide Injection as a contrast medium sparing strategy, the center aims to prevent Major Adverse Kidney Events in patients with Peripheral Arterial Disease.

• Contrast Medium Sparing Techniques
• Carbon Dioxide Injection
• Kidney Event Prevention

This approach not only enhances patient safety but also sets a new standard in vascular intervention protocols.

Specializing in the treatment of atherosclerotic cardiovascular disease, the center is pioneering research in cholesterol management. The focus is on comparing the efficacy of Inclisiran versus bempedoic acid in lowering LDL cholesterol levels, alongside standard care practices. This research is crucial for patients with Hypercholesterolemia, aiming to improve cardiovascular outcomes.

• LDL Cholesterol Reduction
• Inclisiran vs. Bempedoic Acid
• Standard Care Integration

By advancing these therapeutic strategies, the center contributes significantly to the field of lipid management and cardiovascular health.

The center is engaged in cutting-edge research to enhance treatment protocols for multiple myeloma. By evaluating the addition of isatuximab to the standard induction regimen of lenalidomide, bortezomib, and dexamethasone, the research aims to improve minimal residual disease negativity and progression-free survival in newly diagnosed patients.

• Isatuximab Integration
• Induction Regimen Optimization
• Progression-Free Survival Enhancement

This research is pivotal in refining therapeutic approaches and improving long-term outcomes for patients with multiple myeloma.